Bryce Point Capital LLC Invests $801,000 in Moderna, Inc. (NASDAQ:MRNA)

Key Points

• Bryce Point Capital LLC invested $801,000 in Moderna, purchasing 28,268 shares in the company's stock.
• Moderna's stock has a market cap of $13.21 billion and experienced a significant 12-month price fluctuation, ranging from a low of $23.15 to a high of $125.68.
• Analysts have recently lowered their price targets for Moderna, with Morgan Stanley setting a new price objective of $32.00, indicating an "equal weight" rating.

Bryce Point Capital LLC bought a new stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 28,268 shares of the company's stock, valued at approximately $801,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in MRNA. Quantbot Technologies LP boosted its stake in Moderna by 315.3% in the fourth quarter. Quantbot Technologies LP now owns 9,307 shares of the company's stock valued at $387,000 after acquiring an additional 7,066 shares during the last quarter. American Century Companies Inc. lifted its stake in shares of Moderna by 2.7% during the 4th quarter. American Century Companies Inc. now owns 44,619 shares of the company's stock valued at $1,855,000 after buying an additional 1,187 shares in the last quarter. LPL Financial LLC lifted its stake in shares of Moderna by 274.6% during the 4th quarter. LPL Financial LLC now owns 367,878 shares of the company's stock valued at $15,296,000 after buying an additional 269,682 shares in the last quarter. WINTON GROUP Ltd purchased a new stake in shares of Moderna during the 4th quarter valued at approximately $770,000. Finally, UniSuper Management Pty Ltd lifted its stake in shares of Moderna by 69.3% during the 4th quarter. UniSuper Management Pty Ltd now owns 50,953 shares of the company's stock valued at $2,119,000 after buying an additional 20,862 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Price Performance

NASDAQ MRNA traded down $2.49 during trading hours on Thursday, reaching $29.67. 10,038,722 shares of the company's stock traded hands, compared to its average volume of 10,894,363. Moderna, Inc. has a 52-week low of $23.15 and a 52-week high of $122.45. The firm has a market cap of $11.47 billion, a PE ratio of -3.40 and a beta of 1.84. The firm has a 50-day simple moving average of $29.14 and a 200 day simple moving average of $30.38.

Moderna (NASDAQ:MRNA - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported ($2.52) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($2.92) by $0.40. Moderna had a negative net margin of 105.67% and a negative return on equity of 28.69%. The company had revenue of $108.00 million during the quarter, compared to analysts' expectations of $130.35 million. During the same period last year, the company posted ($3.07) EPS. Moderna's revenue was down 35.3% on a year-over-year basis. Sell-side analysts forecast that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. Morgan Stanley lowered their price objective on shares of Moderna from $39.00 to $32.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Cowen assumed coverage on shares of Moderna in a research report on Sunday, July 13th. They set a "hold" rating on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $33.00 to $26.00 and set an "underweight" rating on the stock in a research report on Thursday, May 22nd. Barclays restated an "equal weight" rating on shares of Moderna in a research report on Sunday, July 13th. Finally, William Blair reaffirmed a "market perform" rating on shares of Moderna in a report on Monday, June 2nd. Four equities research analysts have rated the stock with a sell rating, seventeen have assigned a hold rating, three have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $46.11.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.